ONCOTracker and The Binding Site have entered an agreement to develop and commercialize a new test that measures serum levels of the B-cell maturation antigen (sBCMA) protein to monitor people with blood cancers, including multiple myeloma. Under the agreement, The Binding Site has gained exclusive rights to commercialize this test worldwide. ONCOTracker, which has patented technology to measure this biomarker in myeloma patients, will continue to support The Binding Site in its research and development…
You must be logged in to read/download the full post.
The post ONCOTracker, Binding Site Team Up to Develop sBCMA Monitoring Test appeared first on BioNewsFeeds.